{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T16:58:41Z","timestamp":1785430721428,"version":"3.56.0"},"reference-count":23,"publisher":"American Association for Cancer Research (AACR)","issue":"3","license":[{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":30,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA 238998"],"award-info":[{"award-number":["R01CA 238998"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007316","name":"Division of Cancer Prevention, National Cancer Institute","doi-asserted-by":"publisher","award":["U24CA180803"],"award-info":[{"award-number":["U24CA180803"]}],"id":[{"id":"10.13039\/100007316","id-type":"DOI","asserted-by":"publisher"}]},{"name":"NCORP","award":["UG1CA189867"],"award-info":[{"award-number":["UG1CA189867"]}]},{"name":"NRG Oncology Operations","award":["U10CA180868"],"award-info":[{"award-number":["U10CA180868"]}]},{"name":"NRG Oncology SDMC","award":["U10CA180822"],"award-info":[{"award-number":["U10CA180822"]}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>NRG\/RTOG 1016 was a phase III noninferiority trial comparing IMRT + cisplatin versus IMRT + cetuximab for human papillomavirus\u2013positive oropharyngeal squamous cell cancer (HPV+ OPSCC). A germline mutation (the KRAS-variant) previously identified patients with improved outcomes to radiation + cetuximab + cisplatin; thus, we investigated whether there may be similar benefits for IMRT + cetuximab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods:<\/jats:title>\n                    <jats:p>562 patients were tested, with 16% positive for the KRAS-variant. Clinical endpoints were per NRG\/RTOG 1016, and hazard ratios (HR) were estimated by Cox models. Negative binomial regression modeled treatment-related acute and late grade 3 to 5 adverse events (AE). All models included KRAS, assigned treatment, their interaction, and other prognostic variables tested at two-sided 0.05.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>There was no association between the KRAS-variant and clinical outcomes. There were higher local\u2013regional failure rates (LRF) in nonvariant patients treated with cetuximab [HR = 1.83 (1.19\u20132.82)] versus KRAS-variant patients [HR (95% CI), 0.90 (0.34\u20132.41)]. Grade 3 to 4 acute mucositis was higher in nonvariant patients treated with cetuximab [OR = 1.41 (95% CI, 0.98\u20132.03)] and lower in KRAS-variant patients [OR = 0.60 (95% CI, 0.25\u20131.41)]. However, the mean late toxicity ratio was lower in nonvariant patients [0.55 (95% CI, 0.35\u20130.87)] versus KRAS-variant patients [1.62 (95% CI, 0.57\u20134.62)]. KRAS by treatment interaction for acute and late AEs was not significant (P = 0.0717 and 0.0659, respectively).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Possible lower LRF and less acute toxicity with cetuximab versus cisplatin for KRAS-variant patients seem to be offset by potentially increased late toxicity. Further evaluation of this class of biomarkers is warranted.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>Germline microRNA-disrupting biomarkers are functional biomarkers being studied to help guide treatment personalization in cancer. The work in this study is a hypothesis-generating evaluation of the KRAS-variant as a potential biomarker to help predict outcomes and toxicity in patients with head and neck cancer treated with radiation and cetuximab. Findings from this work suggest that these biomarkers may have the potential to differentiate patients at risk of acute versus late toxicity, supporting further study of these biomarkers in radiation studies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-25-0551","type":"journal-article","created":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T08:56:02Z","timestamp":1772787362000},"page":"706-713","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The KRAS-Variant and Cetuximab in HPV-Positive Oropharyngeal Cancer: Results from the NRG\/RTOG 1016 Trial"],"prefix":"10.1158","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5096-3281","authenticated-orcid":false,"given":"Joanne B.","family":"Weidhaas","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/046rm7j60","id-type":"ROR","asserted-by":"publisher"}],"name":"UCLA 1 , Los Angeles, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0571-7839","authenticated-orcid":false,"given":"Jonathan","family":"Harris","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/050draa26","id-type":"ROR","asserted-by":"publisher"}],"name":"NRG Oncology 2 Statistics and Data Management Center, , Philadelphia, Pennsylvania."},{"name":"3American College of Radiology, Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8145-5749","authenticated-orcid":false,"given":"Maura L.","family":"Gillison","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"The University of Texas MD Anderson Cancer Center 4 , Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1718-9642","authenticated-orcid":false,"given":"Dukagjin","family":"Blakaj","sequence":"additional","affiliation":[{"name":"5Ohio State University Comprehensive Cancer Center, Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4865-8085","authenticated-orcid":false,"given":"Greg A.","family":"Krempl","sequence":"additional","affiliation":[{"name":"6University of Oklahoma College of Medicine, Oklahoma City, Oklahoma."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1496-9878","authenticated-orcid":false,"given":"Kristin","family":"Higgins","sequence":"additional","affiliation":[{"name":"7Emory University Hospital, Winship Cancer Institute, Atlanta, Georgia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5977-6004","authenticated-orcid":false,"given":"Jack","family":"Phan","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"The University of Texas MD Anderson Cancer Center 4 , Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8163-0544","authenticated-orcid":false,"given":"Neal E.","family":"Dunlap","sequence":"additional","affiliation":[{"name":"8The James Graham Brown Cancer Center at University of Louisville, Louisville, Kentucky."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6058-4258","authenticated-orcid":false,"given":"Shazia T.","family":"Mahamood","sequence":"additional","affiliation":[{"name":"9Allan Blair Cancer Centre, Regina, Saskatchewan, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1112-3781","authenticated-orcid":false,"given":"Jennifer","family":"Dorth","sequence":"additional","affiliation":[{"name":"10University Hospitals Seidman Cancer Center, Cleveland, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6417-2483","authenticated-orcid":false,"given":"Jimmy J.","family":"Caudell","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01xf75524","id-type":"ROR","asserted-by":"publisher"}],"name":"Moffitt Cancer Center 11 , Tampa, Florida."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-9114-1246","authenticated-orcid":false,"given":"Anand B.","family":"Desai","sequence":"additional","affiliation":[{"name":"12Summa Health System \u2013 Akron Campus, Akron, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5730-2099","authenticated-orcid":false,"given":"Thomas J.","family":"Galloway","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/0567t7073","id-type":"ROR","asserted-by":"publisher"}],"name":"Fox Chase Cancer Center 13 , Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-9523-9642","authenticated-orcid":false,"given":"J. Daniel","family":"Pennington","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/024j7f958","id-type":"ROR","asserted-by":"publisher"}],"name":"Southeast Clinical Oncology Research Consortium 14 NCORP, , Winston-Salem, North Carolina."},{"name":"15Radiation Oncology Associates, Richmond, Virginia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4099-712X","authenticated-orcid":false,"given":"Adam","family":"Currey","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00qqv6244","id-type":"ROR","asserted-by":"publisher"}],"name":"Medical College of Wisconsin 16 Zablocki VA Medical Center, , Milwaukee, Wisconsin."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-9477-4534","authenticated-orcid":false,"given":"Jennifer","family":"Lathrop","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/046rm7j60","id-type":"ROR","asserted-by":"publisher"}],"name":"UCLA 1 , Los Angeles, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1021-6625","authenticated-orcid":false,"given":"Pedro A.","family":"Torres-Saavedra","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/050draa26","id-type":"ROR","asserted-by":"publisher"}],"name":"NRG Oncology 2 Statistics and Data Management Center, , Philadelphia, Pennsylvania."},{"name":"3American College of Radiology, Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6203-7771","authenticated-orcid":false,"given":"D. Neil","family":"Hayes","sequence":"additional","affiliation":[{"name":"17University of Tennessee Health Science Center, Memphis, Tennessee."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0779-7476","authenticated-orcid":false,"given":"Sue S.","family":"Yom","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/043mz5j54","id-type":"ROR","asserted-by":"publisher"}],"name":"University of California, San Francisco 18 , San Francisco, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3682-1439","authenticated-orcid":false,"given":"Quynh-Thu","family":"Le","sequence":"additional","affiliation":[{"name":"19Stanford Cancer Institute Palo Alto, Stanford, California."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2026,3,31]]},"reference":[{"key":"2026033107062800500_bib1","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1200\/JCO.2003.01.008","article-title":"An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer","volume":"21","author":"Adelstein","year":"2003","journal-title":"J Clin Oncol"},{"key":"2026033107062800500_bib2","doi-asserted-by":"crossref","first-page":"3582","DOI":"10.1200\/JCO.2007.14.8841","article-title":"Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis","volume":"26","author":"Machtay","year":"2008","journal-title":"J Clin Oncol"},{"key":"2026033107062800500_bib3","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMoa053422","article-title":"Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck","volume":"354","author":"Bonner","year":"2006","journal-title":"N Engl J Med"},{"key":"2026033107062800500_bib4","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S1470-2045(09)70311-0","article-title":"Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival","volume":"11","author":"Bonner","year":"2010","journal-title":"Lancet Oncol"},{"key":"2026033107062800500_bib5","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1185\/03007995.2011.633989","article-title":"Indirect comparison of the efficacy of cetuximab and cisplatin in squamous cell carcinoma of the head and neck","volume":"27","author":"Levy","year":"2011","journal-title":"Curr Med Res Opin"},{"key":"2026033107062800500_bib6","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa0912217","article-title":"Human papillomavirus and survival of patients with oropharyngeal cancer","volume":"363","author":"Ang","year":"2010","journal-title":"N Engl J Med"},{"key":"2026033107062800500_bib7","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(18)32779-X","article-title":"Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial","volume":"393","author":"Gillison","year":"2019","journal-title":"Lancet"},{"key":"2026033107062800500_bib8","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0140-6736(18)32752-1","article-title":"Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial","volume":"393","author":"Mehanna","year":"2019","journal-title":"Lancet"},{"key":"2026033107062800500_bib9","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.ijrobp.2021.04.015","article-title":"Randomized trial of radiation therapy with weekly cisplatin or cetuximab in low-risk HPV-associated oropharyngeal cancer (TROG 12.01) - a Trans-Tasman Radiation Oncology Group Study","volume":"111","author":"Rischin","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026033107062800500_bib10","doi-asserted-by":"crossref","first-page":"4499","DOI":"10.1158\/1078-0432.CCR-14-0348","article-title":"A let-7 microRNA-binding site polymorphism in KRAS predicts improved outcome in metastatic colorectal cancer (mCRC) patients treated with salvage cetuximab\/panitumumab monotherapy","volume":"20","author":"Saridaki","year":"2014","journal-title":"Clin Cancer Res"},{"key":"2026033107062800500_bib11","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1093\/annonc\/mdu367","article-title":"A 3\u2032-UTR KRAS-variant is associated with cisplatin resistance in patients with recurrent and\/or metastatic head and neck squamous cell carcinoma","volume":"25","author":"Chung","year":"2014","journal-title":"Ann Oncol"},{"key":"2026033107062800500_bib12","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1158\/2767-9764.CRC-23-0084","article-title":"The inherited KRAS-variant as a biomarker of cetuximab response in NSCLC","volume":"3","author":"Weidhaas","year":"2023","journal-title":"Cancer Res Commun"},{"key":"2026033107062800500_bib13","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/mt.2012.184","article-title":"Cetuximab-mediated tumor regression depends on innate and adaptive immune responses","volume":"21","author":"Yang","year":"2013","journal-title":"Mol Ther"},{"key":"2026033107062800500_bib14","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1158\/1078-0432.CCR-12-2426","article-title":"Cetuximab-activated natural killer and dendritic cells collaborate to trigger tumor antigen-specific T-cell immunity in head and neck cancer patients","volume":"19","author":"Srivastava","year":"2013","journal-title":"Clin Cancer Res"},{"key":"2026033107062800500_bib15","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1007\/s00262-013-1437-3","article-title":"TLR8 stimulation enhances cetuximab-mediated natural killer cell lysis of head and neck cancer cells and dendritic cell cross priming of EGFR-specific CD8+ T cells","volume":"62","author":"Stephenson","year":"2013","journal-title":"Cancer Immunol Immunother"},{"key":"2026033107062800500_bib16","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1001\/jamaoncol.2016.5478","article-title":"The KRAS-variant and cetuximab response in head and neck squamous cell cancer: a secondary analysis of a randomized clinical trial","volume":"3","author":"Weidhaas","year":"2017","journal-title":"JAMA Oncol"},{"key":"2026033107062800500_bib17","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1093\/annonc\/mdq315","article-title":"A let-7 microRNA-binding site polymorphism in 3\u2032-untranslated region of KRAS gene predicts response in wild-type KRAS patients with metastatic colorectal cancer treated with cetuximab monotherapy","volume":"22","author":"Zhang","year":"2011","journal-title":"Ann Oncol"},{"key":"2026033107062800500_bib18","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1093\/annonc\/mdq704","article-title":"KRAS let-7 LCS6 SNP predicts cetuximab efficacy in KRASwt metastatic colorectal cancer patients: does treatment combination partner matter?","volume":"22","author":"Zhang","year":"2011","journal-title":"Ann Oncol"},{"key":"2026033107062800500_bib19","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1038\/tpj.2010.9","article-title":"Genetic modulation of the Let-7 microRNA binding to KRAS 3\u2032-untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximab-irinotecan","volume":"10","author":"Graziano","year":"2010","journal-title":"Pharmacogenomics J"},{"key":"2026033107062800500_bib20","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0360-3016(00)00435-1","article-title":"TGF-beta1 and radiation fibrosis: a master switch and a specific therapeutic target?","volume":"47","author":"Martin","year":"2000","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026033107062800500_bib21","first-page":"2019","article-title":"A phase 2 trial of five-day neoadjuvant radiation therapy for patients with high-risk primary soft tissue sarcoma","volume":"3524","author":"Kalbasi","year":"2020","journal-title":"Clin Cancer Res"},{"key":"2026033107062800500_bib22","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.radonc.2021.12.040","article-title":"Germline variants disrupting microRNAs predict long-term genitourinary toxicity after prostate cancer radiation","volume":"167","author":"Kishan","year":"2022","journal-title":"Radiother Oncol"},{"key":"2026033107062800500_bib23","first-page":"100594","article-title":"Application of a genetic signature of late GU toxicity in SCIMITAR, a Post-op SBRT trial","volume":"39","author":"Kishan","year":"2023","journal-title":"Clin Transl Radiat Oncol"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-25-0551\/3745997\/crc-25-0551.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/3\/706\/3756757\/crc-25-0551.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/3\/706\/3756757\/crc-25-0551.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T11:06:35Z","timestamp":1774955195000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/6\/3\/706\/776769\/The-KRAS-Variant-and-Cetuximab-in-HPV-Positive"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,1]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-25-0551","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.31900095","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31900083","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31900071","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31900089","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31900077","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31900104","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31900065","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31900059","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31900122","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31900110","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31900119","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31900107","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31900092","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31900080","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31900074","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31900062","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31900056","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31900101","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31900113","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31900098","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31900086","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31900125","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31900131","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31900068","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31900128","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31900116","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.8393601","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,1]]}}}